Hengrui signs USD 15.2 billion deal
Hengrui Medicine has signed a global partnership with Bristol Myers Squibb covering 13 early-stage projects in oncology, hematology, and immunology. Announced on May 12, the deal has a potential total value of USD 15.2 billion, including USD 950 million in upfront and milestone payments.